Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathy.

van Steensel L, van Hagen PM, Paridaens D, Kuijpers RW, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA.

Br J Ophthalmol. 2011 May;95(5):735-8. doi: 10.1136/bjo.2010.192302. Epub 2011 Feb 10.

PMID:
21310803
2.

Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.

van Steensel L, Paridaens D, Schrijver B, Dingjan GM, van Daele PL, van Hagen PM, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA.

Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3091-8. doi: 10.1167/iovs.08-2443. Epub 2009 Feb 21.

PMID:
19234339
3.

Orbit-infiltrating mast cells, monocytes, and macrophages produce PDGF isoforms that orchestrate orbital fibroblast activation in Graves' ophthalmopathy.

van Steensel L, Paridaens D, van Meurs M, van Hagen PM, van den Bosch WA, Kuijpers RW, Drexhage HA, Hooijkaas H, Dik WA.

J Clin Endocrinol Metab. 2012 Mar;97(3):E400-8. doi: 10.1210/jc.2011-2697. Epub 2012 Jan 11.

PMID:
22238384
4.

The tyrosine kinase inhibitor dasatinib effectively blocks PDGF-induced orbital fibroblast activation.

Virakul S, Dalm VA, Paridaens D, van den Bosch WA, Hirankarn N, van Hagen PM, Dik WA.

Graefes Arch Clin Exp Ophthalmol. 2014 Jul;252(7):1101-9. doi: 10.1007/s00417-014-2674-7. Epub 2014 May 30.

PMID:
24874745
5.

Platelet-derived growth factor-BB: a stimulus for cytokine production by orbital fibroblasts in Graves' ophthalmopathy.

van Steensel L, Paridaens D, Dingjan GM, van Daele PL, van Hagen PM, Kuijpers RW, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA.

Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1002-7. doi: 10.1167/iovs.09-4338. Epub 2009 Sep 24.

PMID:
19797221
6.

Anti-inflammatory effect of quercetin in a whole orbital tissue culture of Graves' orbitopathy.

Yoon JS, Chae MK, Lee SY, Lee EJ.

Br J Ophthalmol. 2012 Aug;96(8):1117-21. doi: 10.1136/bjophthalmol-2012-301537. Epub 2012 Jun 2.

PMID:
22661653
7.
8.

Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.

Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, Huvos AG, Sowers R, Meyers PA, Healey JH, Gorlick R.

Cancer. 2008 May 15;112(10):2119-29. doi: 10.1002/cncr.23437.

9.

Platelet-derived growth factor: a key factor in the pathogenesis of graves' ophthalmopathy and potential target for treatment.

Virakul S, van Steensel L, Dalm VA, Paridaens D, van Hagen PM, Dik WA.

Eur Thyroid J. 2014 Dec;3(4):217-26. doi: 10.1159/000367968. Epub 2014 Dec 6. Review.

10.

Platelet-Derived Growth Factor-BB Enhances Adipogenesis in Orbital Fibroblasts.

Virakul S, Dalm VA, Paridaens D, van den Bosch WA, Mulder MT, Hirankarn N, van Hagen PM, Dik WA.

Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5457-64. doi: 10.1167/iovs.15-17001.

PMID:
26284551
11.

Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves' ophthalmopathy.

Zhang C, Zhang X, Ma L, Peng F, Huang J, Han H.

Endocrine. 2012 Apr;41(2):248-55. doi: 10.1007/s12020-012-9600-8. Epub 2012 Jan 12.

PMID:
22237514
12.

TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients.

Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF.

Clin Endocrinol (Oxf). 2003 Mar;58(3):280-7.

PMID:
12608932
13.
14.

Comparative suppressive effects of tyrosine kinase inhibitors imatinib and nilotinib in models of autoimmune arthritis.

Akashi N, Matsumoto I, Tanaka Y, Inoue A, Yamamoto K, Umeda N, Tanaka Y, Hayashi T, Goto D, Ito S, Sekiguchi K, Sumida T.

Mod Rheumatol. 2011 Jun;21(3):267-75. doi: 10.1007/s10165-010-0392-5. Epub 2010 Dec 29.

PMID:
21188449
15.

Effect of tanshinone IIA in an in vitro model of Graves' orbitopathy.

Rhiu S, Chae MK, Lee EJ, Lee JB, Yoon JS.

Invest Ophthalmol Vis Sci. 2014 Aug 26;55(9):5900-10. doi: 10.1167/iovs.14-14008.

PMID:
25159204
16.

Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

Appel S, Boehmler AM, Grünebach F, Müller MR, Rupf A, Weck MM, Hartmann U, Reichardt VL, Kanz L, Brümmendorf TH, Brossart P.

Blood. 2004 Jan 15;103(2):538-44. Epub 2003 Sep 22.

17.

The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation.

Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, Weiss G, Tilg H.

Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13622-7. Epub 2005 Sep 8.

18.

The orbital fibroblast: a key player and target for therapy in graves' ophthalmopathy.

van Steensel L, Dik WA.

Orbit. 2010 Aug;29(4):202-6. doi: 10.3109/01676831003668443. Review.

PMID:
20812837
19.

Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

Distler JH, Jüngel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O.

Arthritis Rheum. 2007 Jan;56(1):311-22.

20.

The effect of imatinib mesylate (Glivec) on human tumor-derived cells.

Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA.

Anticancer Drugs. 2006 Jul;17(6):649-55.

PMID:
16917210
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk